---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-056728"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:13:22.006416+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 60 Degrees Pharmaceuticals enrolls first patient in tafenoquine babesiosis trial

## Summary
- First patient enrolled in randomized, double-blind, placebo-controlled trial at Tufts Medical Center.
- Study is first and only clinical trial evaluating tafenoquine in human babesiosis patients.
- Endpoints: time to sustained clinical resolution and molecular cure via FDA-approved nucleic acid test.
- Study targets at least 24 and up to 33 patients; interim analysis planned; recruitment during 2024 tick season.
- Tafenoquine (ARAKODA) already FDA-approved for malaria prophylaxis; orphan drug designation for babesiosis.

## SEC filing metadata
- accession: 0001213900-24-056728
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390024056728/0001213900-24-056728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390024056728/ea0208661-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-056728
- JSON: https://secwatch.observer/filing/0001213900-24-056728.json
- Plain text: https://secwatch.observer/filing/0001213900-24-056728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.